Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Sorrento Therapeutics, Inc.
This PHASE1 trial investigates Relapsed or Refractory Multiple Myeloma and is currently completed. Sorrento Therapeutics, Inc. leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Aug 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sorrento Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .